Plus   Neg

DexCom Names Steven Pacelli COO, Jorge Valdes Chief Technical Officer - Update

DexCom, Inc. (DXCM), a developer of continuous glucose monitoring systems for ambulatory use, said Tuesday that it appointed Steven Pacelli to the newly created position of Chief Operating Officer. DexCom also named Jorge Valdes to the newly created position of Chief Technical Officer.

Pacelli will be responsible for the strategic and operational leadership of DexCom's sales, marketing and other core commercial functions, while Valdes will assume responsibility for DexCom's research and development function.

In their new roles, both Pacelli and Valdes will continue to report to Terry Gregg, DexCom's President and Chief Executive Officer.

The San Diego, California-based company noted that Pacelli has been its Chief Administrative Officer since December 2008, overseeing finance, corporate development, managed care, legal, human resources, intellectual property and investor relations functions. Valdes has served as DexCom's Senior Vice President of Operations since July 2007, responsible for overseeing the company's manufacturing, engineering, and information technology departments.

Pacelli joined DexCom in April 2006, and was Vice President of Legal Affairs. From July 2007 to December 2008, he served as Senior Vice President of Corporate Affairs. Prior to DexCom, Pacelli served as a corporate attorney with Stradling Yocca Carlson & Rauth from March 2003 to April 2006. He has also worked with Axcelerant, Inc. and Flashcom, Inc.

The new Chief Technical Officer, Valdes, previously served as DexCom's Vice President of Engineering from November 2005 to July 2007. Prior to that, he was with Advanced Fibre Communications, or AFC, and Racal-Datacom, Inc.

Commenting on the appointments, Gregg said, "Steve's appointment will also provide me with the opportunity to direct more of my energies on developing and refining our corporate strategy, and to enhancing DexCom's external relationships with customers, shareholders, and key constituents, both domestically and internationally. As our product portfolio continues to grow and we tap new opportunities and markets around the globe, operational excellence is critical to achieving our goals."

DXCM closed Monday's regular trading session at $11.46, down $0.01, on a volume of 247,400 shares.

For comments and feedback contact: editorial@rttnews.com

Follow RTT